| anandamide |
drug |
9 |
7 |
AEA, N-arachidonoylethanolamine, endocannabinoid anandamide, endogenous anandamide, endogenous cannabinoid anandamide |
| ancestry |
phenotype |
14 |
8 |
ancestry, ancestry vectors, self-identified ancestry |
| ancestry groups |
cohort |
6 |
2 |
|
| ancestry informative markers |
variant |
2 |
— |
AIMs |
| ancestry principal components |
drug |
5 |
3 |
Ancestry PCs, PCs, first two ancestry principal components, principal components |
| anesthetics |
drug |
7 |
5 |
anesthetic, anesthetics, general anesthesia, inhaled anesthetics |
| Angelman syndrome |
phenotype |
3 |
1 |
Angelman |
| anger |
phenotype |
9 |
6 |
trait anger |
| angiogenesis |
phenotype |
6 |
3 |
|
| anhedonia |
phenotype |
13 |
12 |
anhedonia scores, anhedonic behaviors, anhedonic symptoms |
| animal models |
cohort |
38 |
17 |
animal models, animals, laboratory animals, mice, mouse models, mouse models of AD, rodent, rodent models of FASD, transgenic mice |
| animals |
cohort |
17 |
7 |
animal subjects, rodent cohort, rodents, subjects |
| ANK3 |
gene |
8 |
7 |
ANK3 region, ankyrin 3, ankyrin G, ankyrin-G, node of Ranvier (ankyrin G) |
| ANKK1 |
gene |
18 |
16 |
Ankyrin Repeat and Kinase Domain Containing 1, ankyrin repeat and kinase domain containing 1 |
| ANNOVAR |
drug |
2 |
2 |
|
| anorexia nervosa |
phenotype |
33 |
22 |
AN, AN diagnosis, Anorexia, DSM-IV AN, acute AN, anorexia, anorexia nervosa, eating disorder-anorexia, modified DSM-IV AN |
| anthropometric traits |
phenotype |
9 |
4 |
|
| antibodies |
drug |
2 |
— |
|
| anticipation |
phenotype |
2 |
2 |
|
| anti-depressants |
drug |
2 |
1 |
|
